No pharmaceutical opinion available for this interaction.
Ritonavir may increase the metabolism (UGT) and decrease the plasma concentration of Canagliflozin.
3A4 and 2D6 (major), 1A2 and 2B6 (minor), 5 metabolites, one of which has a weak concentration of an active metabolite (M-2), transporters: MRP1, MRP2, P-gp
2B6, 2C8, 2C9, 1A2, 2C19 (moderate) UGT (moderate)
3A4 (potent) and 2D6 (moderate), transporters: BCRP, OATP1A2, OATP1B1, OATP1B3, MRP1, MRP2, OCT1, OCT2, P-gp
UGT1A9 and 2B4 (mainly), P-gp, BCRP, MRP2
3A4, 2B6, 2C8, 2C9, P-gp (weak in vitro)
Possible decrease of clinical efficacy.
Monitor for clinical efficacy.
Consider increasing the dose to 300 mg in patients who tolerate canagliflozin 100 mg QD and with CrCl ≥ 60ml/min.
Metformin, DPP-4 Inhibitors, GLP-1 Agonists
Ref #3184 : Co-administration of 600 mg rifampicin, a potent UGT inducer, and a single dose of canagliflozin 300 mg (after 8 days of once daily rifampicin 600 mg) resulted in a 51% and 28% decrease in repaglinide AUC and Cmax, respectively.